[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$nvct
Nuvectis Pharma sees increased social engagement with discussions on portfolio performance and trading activity. Community interest is driven by the company's cancer resistance inhibitor, NXP-900, and the recent addition of a new board member, Juan Sanchez MD, to the Board of Directors.
About $nvct
Nuvectis Pharma (NVCT) is a pharmaceutical company.
Insights #
- $nvct engagements is up XXXXXX% from the previous week.
Engagements: XXX #
Engagements 24-Hour Time-Series Raw Data
Current Value: XXX
Daily Average: XXXXX
1 Week: XXXXX +129%
1 Month: XXXXX -XX%
1-Year High: XXXXXX on 2025-09-10
1-Year Low: X on 2025-08-24
| Social Network | X |
|---|---|
| Engagements | XXX |
Mentions: X #
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: XX
1-Year High: XXX on 2025-06-27
1-Year Low: X on 2025-09-17
| Social Network | X |
|---|---|
| Mentions | X |
Creators: X #
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $nvct in the last XX hours which is up XXX% from X in the previous XX hours
Daily Average: XX
1-Year High: XXX on 2025-06-27
1-Year Low: X on 2025-06-05
Top assets mentioned In the posts about $nvct in the last XX hours
Axsome Therapeutics, Inc (AXSM) TG Therapeutics, Inc. (TGTX) Open Custody Protocol (OPEN) Ethereum (ETH) uniQure N.V. (QURE)
Top topics mentioned In the posts about $nvct in the last XX hours
jordan, $axsm, $tgtx, investment, pharma, $14k, $13k, edinburgh, university of, 1b, combo, arms, $open, ethereum, coins layer 1, $imrx, $nktr, $qure
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$NVCT NXP900 #ANE2025 abstract title 10/23: A099 NXP900 a novel YES1/SRC kinase inhibitor currently in clinical development potently inhibits tumor growth in FAT1 mutated xenograft models. Asier Unciti-Broceta. University of Edinburgh Edinburgh UK. The new FAT1-mutant PDX work extends the preclinical models into human-derived systemsreinforcing the translational bridge that defines NXP900s biomarker-guided clinical strategy. ➡ As the first human PDX study of NXP900 it builds on prior TNBC in-vivo data and substantiates the logic behind FAT1 loss as a key biomarker for patient enrichment in"
X Link @JD4for4 2025-10-13T18:11Z 8285 followers, 1774 engagements
"PORTFOLIO - by size $OPEN - XX% covered calls OTM $AXSM $NVCT $ETH $MARA $IMRX 100x parlay - NVCT & Selling down positions to add OPEN worked well with stock up almost 3x"
X Link @DalvinVarnado 2025-10-06T13:26Z 31.8K followers, XXX engagements
"My model bio portfolio as of Sep XX 2025 $NVCT XX% $NKTR XX% $QURE XX% $TGTX XX% $AXSM XX% $PRQR X% While intended $IMRX as a LT hold sold to lock in Aug buys at $XX. OS XX% beat best case & AH $XX confirmed itthen mgmt torpedoed it w/ $200M ($350M cap) raise before data was even presented. move. Bio investing hard enough even w/ good mgmt. Ph3 data X yrs out & may revisit but likely better oppsremoving from portfolio & rotating into $QURE 0➡20% & $NKTR XX% ➡20%"
X Link @JD4for4 2025-10-03T14:33Z 8264 followers, 5738 engagements
"$NVCT Nuvectis Pharma: X trades $14K vs $13K avg (1.13x). $14K calls / $X puts. $STC Stewart Information Services: X trades $14K vs $13K avg (1.14x). $14K calls / $X puts"
X Link @highnihilism 2025-09-30T12:13Z XXX followers, XXX engagements